Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026
Methods to Include Environmental Impacts in a Cost-Effectiveness Analysis: A Case Study of Surveillance Imaging After Treatment for Stage III Melanoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Williams Jake T W, Bell Katy J L, McAlister Scott, Morton Rachael L
Аннотация
OBJECTIVES: To demonstrate methods to include carbon emissions in a cost-effectiveness analysis of different positron emission tomography and computed tomography surveillance imaging schedules for detecting metastasis in patients treated for stage III melanoma.
METHODS: Decision-analytic modeling was used to compare 12-monthly imaging with no routinely scheduled imaging. The health outcome was the proportion of patients without a false-negative result for a distant metastasis. Health system costs were included in 2023 Australian dollars. A 5% discount per year was applied. Carbon emissions were obtained from existing studies. Four methods were demonstrated: (1) reporting emissions in parallel, (2) the incremental carbon footprint cost ratio, (3) the incremental carbon footprint effectiveness ratio, and (4) integrating emissions as a cost in the incremental cost-effectiveness ratio (ICER).
RESULTS: In the base case, 12-monthly imaging was more expensive and more effective than no scheduled imaging, with an ICER of $71 757 per false-negative avoided. Carbon emissions were higher for 12-monthly imaging (1497 kg CO2-e) than no routine imaging (1037 kg CO2-e). The incremental carbon footprint cost ratio was 0.2 kg CO2-e per additional dollar spent. The incremental carbon footprint effectiveness ratio was 17 331 kg CO2-e per false-negative avoided. Valuing emissions using New South Wales carbon values increased the ICER modestly to $73 919 per false-negative avoided. Using the mortality-accounting social cost of carbon increased the ICER to $107 297 per false-negative avoided.
CONCLUSIONS: Parallel methods are difficult to interpret without agreed value thresholds. Integrated methods meaningfully altered the results of the base-case analysis when higher monetary values of carbon emissions were used.
METHODS: Decision-analytic modeling was used to compare 12-monthly imaging with no routinely scheduled imaging. The health outcome was the proportion of patients without a false-negative result for a distant metastasis. Health system costs were included in 2023 Australian dollars. A 5% discount per year was applied. Carbon emissions were obtained from existing studies. Four methods were demonstrated: (1) reporting emissions in parallel, (2) the incremental carbon footprint cost ratio, (3) the incremental carbon footprint effectiveness ratio, and (4) integrating emissions as a cost in the incremental cost-effectiveness ratio (ICER).
RESULTS: In the base case, 12-monthly imaging was more expensive and more effective than no scheduled imaging, with an ICER of $71 757 per false-negative avoided. Carbon emissions were higher for 12-monthly imaging (1497 kg CO2-e) than no routine imaging (1037 kg CO2-e). The incremental carbon footprint cost ratio was 0.2 kg CO2-e per additional dollar spent. The incremental carbon footprint effectiveness ratio was 17 331 kg CO2-e per false-negative avoided. Valuing emissions using New South Wales carbon values increased the ICER modestly to $73 919 per false-negative avoided. Using the mortality-accounting social cost of carbon increased the ICER to $107 297 per false-negative avoided.
CONCLUSIONS: Parallel methods are difficult to interpret without agreed value thresholds. Integrated methods meaningfully altered the results of the base-case analysis when higher monetary values of carbon emissions were used.